Highlights Orgenesis Inc.

Equities

ORGS

US68619K2042

Delayed Nasdaq Other stock markets 04:30:01 2024-05-02 pm EDT			5-day change	1st Jan Change
0.543 ^USD	+3.31%		+7.74%	+8.45%

Apr. 16	North American Morning Briefing : Powell Comments, -2-	DJ
Apr. 15	Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Germfree and Orgenesis Inc. Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility	Apr. 10	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Orgenesis Inc. agreed to acquire 25% stake in Octomera LLC from MM OS Holdings, L.P.	Jan. 30	CI
Orgenesis Inc. entered into a binding Term Sheet agreement to acquire Octomera LLC from MM OS Holdings, L.P.	Jan. 23	CI
Earnings Flash (ORGS) ORGENESIS Reports Q3 Revenue $110,000	Nov. 13	MT
Orgenesis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States	23-09-21	CI
Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.	23-08-10	CI
Orgenesis Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Morgenesis LLC Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors	23-05-18	CI
Earnings Flash (ORGS) ORGENESIS Reports Q1 Revenue $7M	23-05-10	MT
Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.	23-05-10	CI
Orgenesis Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
ORGENESIS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-22	AQ
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.	23-03-22	CI
Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Earnings Flash (ORGS) ORGENESIS Posts Q4 Revenue $13.6M	23-03-21	MT
Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California	23-03-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Orgenesis Inc.

Equities

ORGS

US68619K2042

Highlights

Filters